✦ LIBER ✦
NILVAD: An investigator initiated multi-centre placebo-controlled phase III trial of Nilvadipine, a calcium channel blocker, in mild-to-moderate Alzheimer's disease
✍ Scribed by Lawlor, Brian; Crawford, Fiona; Rikkert, Marcel Olde; Mullan, Michael; Tsolaki, Magda; Borjesson, Anne; Pasquier, Florence; Riepe, Matthias; Kenny, Rose Anne; Howard, Robert; Gaynor, Siobhan; Molloy, William
- Book ID
- 122852089
- Publisher
- Elsevier Science
- Year
- 2011
- Tongue
- English
- Weight
- 52 KB
- Volume
- 7
- Category
- Article
- ISSN
- 1552-5260
No coin nor oath required. For personal study only.